Nl-Fr

View abstract

This abstract is assigned to session Free Papers Session 4
Presentation preference Oral presentation
TitlePrognostic factors for the introduction of biological therapy in patients with juvenile idiopathic arthritis-related uveitis
PurposePurpose of this retrospective study was to clinically characterize a cohort of patients with juvenile idiopathic arthritis(JIA) related uveitis and identify prognostic factors present at JIA onset that may predict the need for administering biologicals for uveitis control.
MethodsThe study was conducted at the Clinical Rheumatology Units of IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico and at ASST Gaetano Pini, Milan, Italy between January 2002 and December 2020. Clinical data was collected from patients’ charts, including the type of arthritis, laterality of uveitis, ophthalmic complications at the first presentation, erythrocyte sedimentation rate, and C reactive protein levels.
Cox regression analysis was performed to determine whether any of the collected parameters were associated with the need for administering biological therapy for uveitis control.
ResultsA total of 99 patients (82 females; mean age at JIA onset: 3.88±3.11 years) were included in the study. Of these, 25 had a polyarticular disease and 35 had bilateral uveitis. All patients received disease-modifying antirheumatic drugs. During the follow-up period (mean 9.15±4.71 years), 65 patients required the introduction of biological therapy to control the uveitis.
A higher risk of requiring biological therapy was associated with oligoarticular disease (hazard ratio [HR]: 2.05; 95% confidence interval [CI]: 1.19-3.54, p=0.010) and a longer time between the onset of JIA and the onset of uveitis (HR: 1.11; 95% CI: 1.03-1.2, p=0.007).
ConclusionThese findings could potentially assist clinicians in identifying patients who may require more aggressive treatment strategies to manage their disease.
Conflict of interestNo
Authors 1
Last nameMAPELLI
Initials of first name(s)C
DepartmentOphtalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
CityMilan
CountryItaly
Authors 2
Last nameMISEROCCHI
Initials of first name(s)E
DepartmentOcular Immunology and Uveitis Service Department of Ophthalmology. San Raffaele Scientific Institute
CityMilan
CountryItaly
Authors 3
Last nameBERETTA
Initials of first name(s)GB
DepartmentPediatric Rheumatology Pediatric Intermediate Care Unit Fondazione IRCCS Ca’Granda Ospedale Maggiore
CityMilan
CountryItaly
Authors 4
Last nameMARELLI
Initials of first name(s)L
DepartmentEye Clinic San Giuseppe Hospital, IRCCS Multimedica Scientif Institute
CityMilan
CountryItaly
Authors 5
Last nameLEONE
Initials of first name(s)G
DepartmentOphtalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
CityMilan
CountryItaly
Authors 6
Last nameFILOCAMO
Initials of first name(s)G
DepartmentPediatric Rheumatology Pediatric Intermediate Care Unit Fondazione IRCCS Ca’Granda Ospedale Maggiore
CityMilan
CountryItaly
Authors 7
Last nameVIOLA
Initials of first name(s)F
DepartmentOphtalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
CityMilan
CountryItaly
Authors 8
Last nameNASSISI
Initials of first name(s)M
DepartmentOphtalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
CityMilan
CountryItaly
Authors 9
Last nameMINOIA
Initials of first name(s)F
DepartmentPediatric Rheumatology Pediatric Intermediate Care Unit Fondazione IRCCS Ca’Granda Ospedale Maggiore
CityMilan
CountryItaly